Athenex

+1 716.898.86261001 Main Street, Suite 600, Buffalo, New York, 14203

Athenex

Improving the lives of cancer patients everywhere

Athenex acquires Kuur Therapeutics

LEARN MORE

A global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer

LEARN MORE

A deep innovative pipeline

LEARN MORE

Recent News

2021-09-16T02:30:00

Athenex Presents Data from Oral Paclitaxel + Pembrolizumab Phase 1 Study at ESMO 2021

2021-09-15T08:00:00

Athenex to Present at the Oppenheimer 2021 Fall Healthcare Life Sciences & Med Tech Summit

2021-08-05T07:00:00

Athenex Provides Second Quarter 2021 Corporate and Financial Update

2021-07-26T07:00:00

Athenex Announces Additional Licensing Agreements for Tirbanibulin

2021-07-22T08:47:00

Athenex to Provide Corporate and Financial Update for the Second Quarter 2021 on August 5, 2021

2021-07-19T10:51:00

Athenex Announces European Commission Approval of Klisyri® (tirbanibulin) for the Topical Treatment of Actinic Keratosis

2021-07-06T07:00:00

Athenex Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel Plus Encequidar for the Treatment of Metastatic Breast Cancer

2021-06-04T09:05:00

Athenex Presents Data on Oral Docetaxel and Oral Paclitaxel at ASCO2021 Virtual Scientific Program

2021-05-21T09:21:00

Athenex Announces Klisyri® (tirbanibulin) Receives Positive CHMP Opinion from the European Medicines Agency (EMA) for the Treatment of Actinic Keratosis of the Face or Scalp

Our Science

We are focused on discovering and developing novel therapies for treating cancer and addressing unmet medical needs.

Investors

View press releases, events and presentations, and other investment information

Join Our Team

As the Company grows, we are always looking to add talented professionals to join the Athenex family.